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Purpose: This study evaluated the pharmacokinetics of intravitreal vancomycin and
ceftazidime in the aqueous humor ofmacaque eyes filledwith silicone oil in the vitreous
cavity.
Methods: Intravitreal vancomycin (1 mg/0.1 mL) and ceftazidime (2 mg/0.1 mL) were
injected into four normal macaque eyes, four vitrectomized aphakic macaque eyes, and
four previously vitrectomized aphakic macaque eyes filled with silicone oil (silicone oil-
filled eyes). Aqueous humor samples (0.1 mL) were obtained just before injection and
at 2 and 5 hours and 1, 2, 3, 5, 7, and 10 days after injection. In each group, corneal
endothelial cell density (ECD) measurements and electroretinogram (ERG) recordings
were obtained before injection and after 1 month.
Results: The half-lives of vancomycin in the aqueous humor of normal, vitrectomized,
and silicone oil-filled eyes were 29.4, 21.1, and 6.8 hours, respectively, and those of
ceftazidime were 20.4, 5.2, and 3.1 hours, respectively. The maximum vancomycin
aqueous humor concentrations of normal, vitrectomized, and silicone oil-filled eyes
were 151.4, 205.6, and 543.5 μg/mL, respectively, and the maximum ceftazidime
aqueous humor concentrations are 64.6, 260.0, and 1176.3 μg/mL, respectively. There
was no change in ECD, and ERGwas not declined after intravitreal injection in all groups.
Conclusions: The half-lives of vancomycin and ceftazidime in the aqueous humor were
shorter in silicone oil-filled eyes than in normal and vitrectomized eyes. High antibiotic
concentrations in silicone oil-filled eyes seemed to be well tolerated.
Translational Relevance: This study aids in estimating how often an antibiotic should
be intravitreally injected for endophthalmitis of silicone oil-filled eyes.
Introduction
Bacterial endophthalmitis is a potential compli-
cation of ocular surgery and ocular trauma that
could lead to irreversible loss of vision if not treated
promptly.1–3 Since publication of the Endophthalmi-
tis Vitrectomy Study in 1995,1 intravitreal antibi-
otics have been recommended for its treatment.
Vancomycin is nontoxic in clinical doses and is effec-
tive against almost all gram-positive bacteria, includ-
ing methicillin-resistant Staphylococcus aureus.1,4,5 In
the past, aminoglycoside antibiotics, such as amikacin
and gentamicin, were widely used for gram-negative
bacteria1,6,7; however, macular infarction may occur
after intravitreal injection.7 Intravitreal ceftazidime, a
wide spectrum cephem antibiotic, is as effective as
aminoglycosides for gram-negative bacteria but has
a low risk of causing macular infarction.8 Currently,
a combination of vancomycin and ceftazidime is
commonly used for endophthalmitis or suspected
endophthalmitis.6,9,10
Copyright 2021 The Authors
tvst.arvojournals.org | ISSN: 2164-2591 1
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Antibiotics Pharmacokinetics in Silicone Oil Eyes TVST | March 2021 | Vol. 10 | No. 3 | Article 1 | 2
In cases of bacterial endophthalmitis that do not
respond to intravitreal vancomycin and ceftazidime,
vitrectomy is performed to remove the focus of infec-
tion as much as possible. If a retinal tear or detach-
ment is found or caused during vitrectomy, silicone
oil may be a possible tamponade.11–13 Intravitreal
vancomycin and ceftazidime should be continued even
after surgery. In addition, endophthalmitis may occur
after retinal detachment surgery that requires silicone
oil tamponade. In such cases, intravitreal vancomycin
and ceftazidime are necessary after surgery. However,
the pharmacokinetics of these drugs are likely to differ
in silicone oil-filled eyes compared to normal eyes, as
they are not oil-soluble and the volume of water distri-
bution is much smaller in silicone oil-filled eyes.12,14–16
Therefore, the maximum concentrations and excre-
tion rates are expected to be higher in silicone oil-
filled eyes. Not only is it unclear how long effective
antibiotic concentrations can be maintained, but there
is also concern regarding ocular toxicity due to the
temporarily high concentrations of vancomycin and
ceftazidime.
Talwar et al. studied intraocular ciprofloxacin levels
after oral administration in silicone oil-filled eyes
and found that antibiotic levels in the retro-silicone
oil space fluid in silicone oil-filled eyes after oral
administration of ciprofloxacin in two 750-mg doses
exceeded the minimal inhibitory concentration for 90%
(MIC90) of most bacterial species and was higher than
the levels in the vitreous in nonvitrectomized eyes.17
However, to the best of our knowledge, no studies
have been conducted on intraocular pharmacokinetics
of intravitreally injected antibiotics or other drugs in
silicone oil-filled eyes. This study aimed to investigate
the intraocular pharmacokinetics of vancomycin and
ceftazidime and their toxicity in silicone oil-filled eyes
using cynomolgus monkeys.
Methods
This study was conducted in accordance with the
principles of the Association for Research in Vision
and Ophthalmology Statement for the Use of Animals
in Ophthalmic and Vision Research. The animal
research protocol was approved by the Animal Exper-
imentation Committee at Shiga University of Medical
Science (Approval no.: 2017-8-2).
A total of eight male cynomolgus macaques were
used in this study. Eachmacaque was anesthetized with
5 mg/kg intramuscular ketamine hydrochloride and
1 mg/kg intramuscular xylazine hydrochloride. After
povidone-iodine was placed on the conjunctiva of each
eye, four macaques underwent pars plana vitrectomy
with lensectomy of the right eye. Intravitreal injections
of vancomycin and ceftazidime were administered to
four normal eyes and four vitrectomized aphakic eyes.
After povidone-iodine was placed on the conjunctiva
of each eye, vancomycin (1mg/0.1mL) and ceftazidime
(2 mg/0.1 mL) were injected into the vitreous cavity of
the right eye of each macaque using a 30-gauge needle.
Aqueous humor samples (0.1 mL) from the right eye
were obtained with a 29-gauge needle just before injec-
tion and at 2 and 5 hours and 1, 2, 3, 5, 7, and 10 days
after injection.
Three months later, vitreous surgery with silicone
oil (1000 centistoke) tamponade was performed on
the four vitrectomized eyes. The same experiment was
conducted on the four silicone oil-filled eyes. The depth
of the anterior chamber remained normal at all times
after the samples were obtained. All samples were
stored in a freezer at −80°C until analysis.
ECDMeasurement
Endothelial cell density (ECD) was measured by a
noncontact specularmicroscope (TOPCONSP-2000P;
Topcon, Tokyo, Japan) before injection and at 1 month
postoperatively. The macaques were anesthetized for
measurement as described above. Three ECDmeasure-
ments were obtained for each eye and the average value
was calculated.
Electroretinogram Recording
For electroretinogram (ERG) recordings, all
macaques were dark-adapted for 30 minutes prior
to testing and anesthetized as described above. After
complete pupillary dilation in both eyes, retinal ERG
signals were recorded from the cornea using a contact
light-emitting diode stimulator. In the stimulation
paradigm, a series of flashes (20 J, 200 ms duration)
were delivered from the stimulator. The a-waves were
measured from the baseline to the trough of the first
negative response, and the b-waves from the first
trough to the peak of the following positive wave.
Oscillatory potential amplitudes (OP1, OP2, and
OP3) were measured, summed, and designated as
OPs, as previously reported.18,19 ERG was measured
by a portable ERG device (PE-300; Toyo Medical,
Aichi, Japan) before injection and at 1 month postop-
eratively. In silicone oil-filled eyes, the ERG was
measured after removing the silicone oil. Three
measurements were obtained for each eye and the
average value of the amplitude of each waveform was
calculated.
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Determination of Vancomycin and
Ceftazidime Concentrations in Aqueous
Humor
Aqueous humor samples were stored at−80°C until
analysis. Aqueous humor vancomycin and ceftazidime
concentrations were determined using high perfor-
mance liquid chromatography with ultraviolet detec-
tion (HPLC-UV). HPLC analysis was performed
using the Prominence HPLC system (Shimadzu,
Kyoto, Japan). As the deproteinization treatment, 100
μL of acetonitrile containing 6.25 μg/mL of internal
standard tinidazole was added to 20 μL of aqueous
humor sample. After centrifugation at 12,000 rpm for
10 minutes at 4°C, the supernatant was separated and
evaporated to dryness at 40°C. The obtained residue
was reconstituted in 200 μL of sodium phosphate
buffer (20 mM, pH 2.5). Ten microliters of the recon-
stituted solution were injected into the HPLC system
after filtration. Chromatographic separation was
carried out using the Shim-Pack XR-ODS column (75
mm × 3.0 mm) at 40°C. The flow rate was 0.6 mL/min
with the following gradient elution. Sodium phosphate
buffer (20 mM, pH2.5) and acetonitrile were used
as mobile phases A and B, respectively. Then, the
percentage of mobile phase B was set as follows: 0–6.5
minutes, 7.2%; 6.51 to 7.50 minutes, 40%; and 7.51 to
16 minutes, 7.2%. The detection wavelength was 257
nm for ceftazidime and 240 nm for vancomycin and
tinidazole. The calibration curves of vancomycin
and ceftazidime were linear at 0.625–40 and
0.625–100 μg/mL, respectively. The lower limit of
quantification was 0.625 μg/mL.
Pharmacokinetic Analysis
Intraocular pharmacokinetics were analyzed
according to a one-compartment model. If the volume
of distribution in the eyeball is defined as Vd, the clear-
ance from the eyeball as CL, and the dose as D, the
initial concentration (C0) is calculated as D/Vd and the
elimination rate constant (Ke) as CL/V. The half-life
(t1/2) is calculated as ln (2/Ke) and the area under the
ocular concentration-time curve (AUC) is calculated
as D/CL.
Statistical Analysis
Statistical analyses were performed using PASW
Statistics version 18 software (SPSS Japan, Tokyo,
Japan). The Kruskal–Wallis test was used to evaluate
the pharmacokinetics of vancomycin and ceftazidime.
The paired t-test was used to compare differences
between paired data. P < 0.05 was considered signif-
icant.
Simulation of Pharmacokinetics
Intraocular pharmacokinetics were simulated. For
simulation, the dose of the drug was set to 1 mg,
and the clearance value used was calculated from the
aqueous humor drainage rate (2.8 mL/min).20 Volume
of distribution was calculated from the average eyeball
volume of cynomolgus monkeys.21
Results
In the normal eyes (n = 4), mean vancomycin
concentration in the aqueous humor peaked at 151.4
μg/mL at 24 hours (range = 122.5–203.8; Fig. 1) and
the half-life of vancomycin in the aqueous humor
was 29.4 hours (range = 24.7–36.8; Table 1). Mean
vancomycin concentration in the aqueous humor in the
vitrectomized eyes (n= 4) peaked at 205.6 μg/mL at 3.5
hours (range= 181.3–228.9; see Fig. 1) and the half-life
was 21.1 hours (range = 15.3–28.1; see Table 1). Mean
vancomycin concentration in the aqueous humor in the
silicone oil-filled eyes (n = 4) peaked at 543.5 μg/mL
at 4.25 hours (range = 292.7–720.0; see Fig. 1) and
decrease to less than the lower limit of detection on day
5 and thereafter. The half-life was 6.8 hours (range =
4.5–7.9; see Table 1). Mean vancomycin concentration
in the aqueous humor significantly differed among the
three groups at all time points (P < 0.05).
Mean ceftazidime concentration in the aqueous
humor in the normal eyes (n = 4) peaked at 64.6
μg/mL at 19.3 hours (range = 21.4–146.1; Fig. 2)
and the half-life of ceftazidime in the aqueous humor
was 20.4 hours (range = 6.5–35.3; see Table 1). Mean
ceftazidime concentration in the aqueous humor in the
vitrectomized eyes (n= 4) peaked at 260.0 μg/mL at 3.5
hours (range = 250.3–310.5; see Fig. 2) and decreased
to less than the lower limit of detection on day 3 and
thereafter. The half-life was 5.2 hours (range= 3.8–7.9;
see Table 1). Mean ceftazidime concentrations in the
aqueous humor in the silicone oil-filled eyes (n = 4)
peaked at 1176.3 μg/mL at 4.3 hours (range = 571.1–
1420.6; see Fig. 2) and decreased to less than the lower
limit of detection on day 3 and thereafter. The half-
life was 3.1 hours (range = 1.7–5.3; see Table 1). Mean
ceftazidime concentration in the aqueous humor signif-
icantly differed among the 3 groups at 2 hours, 5 hours,
1 day, 3 days, and 5 days (P < 0.05).
In normal eyes, mean ECD before injection and at
1 month after injection was 2992 ± 840 and 3050 ±
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Figure 1. Vancomycin concentrations in the aqueous humor of normal, vitrectomized, and silicone oil-filled eyes after intravitreal injection.
Table 1. Pharmacokinetic Parameters of Vancomycin and Ceftazidime
Vancomycin Ceftazidime
Normal Vitrectomized Silicone Normal Vitrectomized Silicone
Eyes Eyes Oil-Filled Eyes Eyes Eyes Oil-Filled Eyes
(n = 4) (n = 4) (n = 4) (n = 4) (n = 4) (n = 4)
Cmax ± SD, μg/mL 151.4 ± 38.5 205.6 ± 19.7 543.5 ± 187.8 64.6 ± 55.7 260.0 ± 35.6 1176.3 ± 405.0
t1/2 ± SD, h 29.4 ± 5.4 21.1 ± 5.4 6.8 ± 2.3 20.4 ± 14.0 5.2 ± 1.9 3.1 ± 1.9
AUC ± SD, mg.h/mL 11.2 ± 2.8 6.7 ± 1.9 9.2 ± 6.9 1.4 ± 0.5 2.3 ± 0.5 14.2 ± 10.0
Cmax, maximum drug concentration; t1/2, half-life; h, hour; AUC, area under the curve.
807 cells/mm2, respectively. Mean ECD before injec-
tion and at 1 month after injection in vitrectomized
eyes was 2221± 314 and 2143± 290 cells/mm2, respec-
tively. In silicone oil-filled eyes, meanECDbefore injec-
tion and at 1 month after injection was 2387 ± 215
and 1992 ± 161 cells/mm2, respectively. The differences
were not significant.
Amplitudes of the a-wave and b-wave and OPs
before and after intravitreal injection of antibiotics are
shown in Table 2. There was no significant difference
in amplitude or implicit time of each ERG pattern
before and after intravitreal injection of antibiotics in
all groups.
No complications, such as uveitis or endophthalmi-
tis occurred.
A simulation study shows that maximum drug
concentration in the aqueous humor peaked at 322
μg/mL and the half-life in the aqueous humor was 12.8
hours in normal eyes. Maximum drug concentration in
the aqueous humor peaked at 1250 μg/mL and the half-
life in the aqueous humor was 3.3 hours in silicone oil-
filled eyes (Fig. 3).
Discussion
Compared to normal and vitrectomized eyes, we
found that maximum aqueous humor vancomycin
and ceftazidime concentrations were higher in silicone
oil-filled eyes and their half-lives were shorter. Further-
more, these findings were in agreement with our
intraocular pharmacokinetics simulation results.
Especially with vancomycin, the results were in
good agreement with the simulation. Maximum drug
concentration in the normal eye simulation peaked at
322 μg/mL and the half-life was 12.8 hours. Maximum
drug concentration in the silicone oil-filled eyes peaked
at 1250 μg/mL and the half-life was 3.3 hours. The
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Figure 2. Ceftazidime concentrations in the aqueous humor of normal, vitrectomized, and silicone oil-filled eyes after intravitreal injection.
Table 2. ERG Parameters in Normal Eyes, Vitrectomized Eyes, and Silicone Oil-Filled Eyes
Normal Eyes Vitrectomized Eyes Silicon Oil-Filled Eyes
Pre 1M Pre 1M Pre 1M
a wave Amplitude, μV 293.7 ± 31.4 304.0 ± 20.9 345.3 ± 12.3 339.4 ± 15.9 332.0 ± 34.6 327.7 ± 36.0
Implicit time, ms 9.6 ± 0.3 9.7 ± 0.2 9.2 ± 0.2 9.3 ± 0.4 10.4 ± 0.5 10.5 ± 0.4
b wave Amplitude, μV 304.0 ± 20.9 338.0 ± 30.8 391.6 ± 1.5 389.3 ± 2.7 374.7 ± 14.7 373.3 ± 11.2
Implicit time, ms 31.5 ± 2.5 31.2 ± 1.2 33.8 ± 1.7 33.6 ± 1.7 39.8 ± 5.6 34.2 ± 6.2
OPs μV 124.3 ± 15.9 122.7 ± 15.0 146.2 ± 2.8 144.0 ± 10.7 141.3 ± 21.4 136.0 ± 19.3
ERG, electroretinography; Pre, before injection; 1M, 1 month after injection; OPs, sum of amplitudes of oscillatory poten-
tials.
peak concentration is about four times higher and the
half-life is about a quarter shorter in silicone oil-filled
eyes in the simulation. In the current study in normal
eyes, mean vancomycin concentration peaked at 151.4
μg/mL and the half-life was 29.4 hours. In the silicone
oil-filled eyes, mean vancomycin concentration peaked
at 543.5 μg/mL and the half-life was 6.8 hours. The
peak concentration is also about four times and the
half-life is also about a quarter in silicone oil-filled eyes.
The results obtained in macaque eyes are supported
by the simulation. Vancomycin and ceftazidime are
hydrophilic antimicrobials16; therefore, they do not
dissolve in silicone oil. The volume of water distri-
bution is smaller in silicone oil-filled eyes. Therefore,
in the current study, the concentration immediately
after administration was high, and the half-life was
shortened because the drug was rapidly excreted.
Common gram-positive bacteria that cause
endophthalmitis, such as Staphylococcus, Strep-
tococcus, and Enterococcus are almost always
susceptible to vancomycin and concentrations of
5 μg/mL are inhibitory.16,22–28 In this study, the MIC
of vancomycin was set to 5 μg/mL. Because we found
aqueous humor vancomycin concentrations below
the MIC on day 10 for normal eyes, day 5 for vitrec-
tomized eyes, and day 3 for silicone oil-filled eyes,
we recommend intravitreal injection of vancomycin
every 3 days in silicone oil-filled eyes. Common gram-
negative bacteria that cause endophthalmitis, such
as Pseudomonas species, Proteus mirabilis are almost
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Figure 3. Simulation of intraocular pharmacokinetics in the normal eye and silicone oil-filled eye.
always susceptible to ceftazidime, and concentrations
of 5 μg/mL are inhibitory.16,26,27,29–32 In this study,
the MIC of ceftazidime was set at 5 μg/mL. In our
study, aqueous humor ceftazidime concentrations
were belowMIC at 3 days for normal eyes, on day 2 for
vitrectomized eyes, and on day 2 for silicone oil-filled
eyes. Therefore, intravitreal injection of ceftazidime is
recommended every 2 days for silicone oil-filled eyes.
We also found shorter half-lives of vancomycin
and ceftazidime in the aqueous humor in vitrec-
tomized eyes compared with normal eyes. In the
current study, after vitrectomy and lensectomy in
macaque eyes, the vitreous vancomycin half-life short-
ened from 29.4 hours to 21.1 hours and the vitre-
ous ceftazidime half-life decreased from 20.4 hours
to 5.2 hours. Results from previous studies indicate
that vitrectomy with lensectomy shortened the half-
life of intravitreal molecules.33–38 After vitrectomy and
lensectomy in rabbit eyes, the vitreous vancomycin
half-life shortened from 25.1 to 9.0 hours,36 and the
vitreous ceftazidime half-life shortened from 10.1 to
5.1 hours.34 In our past studies, after vitrectomy and
lensectomy in macaque eyes, the half-life shortened
from 2.8 to 1.5 days for bevacizumab,37,38 from 2.3 to
1.4 days for ranibizumab,35 and from 2.2 to 1.5 days for
aflibercept.35 Thus, vitrectomy with lensectomy may
increase intravitreal drug clearance.
No change was found in ECD after intravitreal
antibiotic injection, although silicone oil-filled eyes
exhibited higher peak concentrations of vancomycin
and ceftazidime. Previous studies have showed that
intravitreal injection of vancomycin does not affect
ECD39 and ceftazidime in the aqueous humor does
not affect ECD at concentrations up to 3000 μg/mL.40
We found no changes in ERG patterns after intrav-
itreal antibiotic injection even in silicone oil-filled
eyes showing higher peak concentration of the drugs.
Several previous studies have reported that intravit-
real injection of vancomycin and ceftazidime does not
cause retinal damage.5,6,8,9
Limitations of this study should be mentioned. The
number of experimental cynomolgus monkeys used
was small. Although antibiotic intraocular pharma-
cokinetics reportedly change in the setting of endoph-
thalmitis,22,36,41,42 we did not examine eyes with
endophthalmitis. We clearly showed that intravitreal
injections of vancomycin and ceftazidime did not
damage the cornea and retina for at least 1 month.
However, this time period may not be long enough
to show decreases in endothelial cell density or ERG
changes because silicone oil tamponademay stay inside
the eye for longer than 1 month.
In conclusion, intravitreal injection of vancomycin
and ceftazidime shows higher peak concentration of
the drugs and shorter half-lives in silicone oil-filled
eyes than in vitrectomized and normal eyes. Intravit-
real antibiotic injections for endophthalmitis should be
administered at shorter intervals in silicone oil-filled
eyes.
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